Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1

Interventions

Dexamethasone 33Palonosetron 27Aprepitant 24Ondansetron 23Granisetron 14Calcium Dobesilate 8Therapeutics 7Olanzapine 6fosaprepitant 5dexamethasone acetate 5netupitant, palosentron drug combination 4casopitant 4Doxorubicin 4Cyclophosphamide 4Acupressure 4netupitant 3dolasetron 3Yoga 3Tropisetron 3Surveys and Questionnaires 3Radiotherapy 3Metoclopramide 3Dronabinol 3Analgesia 3ramosetron 2ginger extract 2dexamethasone 21-phosphate 2Vincristine 2Tablets 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Vomiting × Duration of Therapy × Clear all
NCT00092183 2017-05-05

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Merck Sharp & Dohme LLC

Phase 4 Completed
866 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

NCT00092196 2017-05-05

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
820 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡